Chester County News and Community Website
PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has announced its participation in several prominent conferences, where it will present significant findings related to its lead candidate, INO-3107. The presentations will …
INOVIO to Showcase Breakthrough Data on INO-3107 at Major Industry Conferences Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) released its financial results and operational highlights for 2024, marking significant strides in its pipeline and the broader development of DNA medicines.
INOVIO Reports Progress on INO-3107 and DNA Medicine, 2024 Financial Outcomes Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has announced notable interim findings from a Phase 1 clinical trial testing DNA-encoded monoclonal antibodies (DMAbs) for COVID-19. Impressively, 100% of participants who reached …
INOVIO Reports Groundbreaking Results in COVID-19 Antibody Trial Read More PLYMOUTH MEETING, PA —INOVIO (NASDAQ: INO) has announced that it will release its fourth-quarter and year-end 2024 financial results on March 18, 2025, after the market closes. The company will …
INOVIO to Announce Q4 and Year-End 2024 Results on March 18, 2025 Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has unveiled promising peer-reviewed results from its Phase 1/2 clinical trial for INO-3107, a cutting-edge DNA medicine designed to treat recurrent respiratory papillomatosis (RRP). …
INOVIO’s INO-3107 Shows Powerful Potential for Treating Recurrent Respiratory Papillomatosis Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has announced that new research on its investigational immunotherapy, INO-3107, will be presented at the American Association for Cancer Research – Immuno-Oncology conference from …
INOVIO to Highlight Breakthrough Immunotherapy Data at AACR Conference Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. Dr. Jacqueline Shea, the company’s President and CEO, along with Dr. …
INOVIO to Present at Oppenheimer Healthcare Life Sciences Conference Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) revealed its strategic milestones for 2025, positioning the company for significant advancements as it aims to become a commercial-stage biotechnology leader. Central to this …
INOVIO Targets 2025 as Transformational Year with Major Progress on INO-3107 Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has announced new data from a retrospective trial showcasing the long-term benefits of its investigational therapy, INO-3107, for patients with Recurrent Respiratory Papillomatosis (RRP). …
INOVIO Reports Promising Long-Term Data for INO-3107 in Treating RRP Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has announced a stock option grant to a newly hired employee under its 2022 Inducement Plan. The award was approved by INOVIO’s Compensation …
INOVIO Grants Equity Award Under 2022 Inducement Plan Read More